The most prominent report that a kinase-independent function of CDK6 links cell cycle to tumor angiogenesis shows CDK6 participating in p16 and VEGF-A transcriptional regulation in lymphoid malignancies [26], CDK6 acts as a transcriptional regulator on the p16INK4a promoter providing an internal safeguard by negative feedback loop. The gene discussed is CDKN2A; the disease is neoplasm.